High, Katherine A.
Rockefeller University,
United States
2025 Rank: 24846
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Biotechnology
Rank in SubField 1: 492 out of 166615 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 24846 | 26647 |
| Total Cites | 1920 | 2083 |
| H-index | 21 | 22 |
| Hm-index | 6 | 6 |
| Number of Single Authored Papers | 26 | 26 |
| Total Cites to Single Authored Papers | 14 | 14 |
| Number of Single+First Authored Papers | 34 | 34 |
| Total Cites to Single+First Authored Papers | 94 | 94 |
| Number of Single+First+Last Authored Papers | 137 | 137 |
| Total Cites to Single+First+Last Authored Papers | 761 | 810 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 1021 | 1053 |
| Ratio of Total Citations to Distinct Citing Papers | 1.88 | 1.98 |
| Self-Citation Percentage |
7.83%
|
|
High, Katherine A.
Rockefeller University,
United States
2024 Rank: 21623
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Biotechnology
Rank in SubField 1: 450 out of 157372 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 21623 | 22692 |
| Total Cites | 1881 | 2045 |
| H-index | 20 | 21 |
| Hm-index | 7 | 7 |
| Number of Single Authored Papers | 25 | 25 |
| Total Cites to Single Authored Papers | 16 | 16 |
| Number of Single+First Authored Papers | 32 | 32 |
| Total Cites to Single+First Authored Papers | 85 | 87 |
| Number of Single+First+Last Authored Papers | 133 | 133 |
| Total Cites to Single+First+Last Authored Papers | 698 | 733 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 976 | 1010 |
| Ratio of Total Citations to Distinct Citing Papers | 1.93 | 2.02 |
| Self-Citation Percentage |
8.02%
|
|
High, Katherine A.
Spark Therapeutics, Inc.,
United States
2023 Rank: 17807
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Biotechnology
Rank in SubField 1: 418 out of 147556 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 17807 | 19412 |
| Total Cites | 1925 | 2047 |
| H-index | 22 | 22 |
| Hm-index | 7 | 7 |
| Number of Single Authored Papers | 26 | 26 |
| Total Cites to Single Authored Papers | 21 | 21 |
| Number of Single+First Authored Papers | 33 | 33 |
| Total Cites to Single+First Authored Papers | 102 | 102 |
| Number of Single+First+Last Authored Papers | 133 | 133 |
| Total Cites to Single+First+Last Authored Papers | 733 | 769 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 1000 | 1029 |
| Ratio of Total Citations to Distinct Citing Papers | 1.93 | 1.99 |
| Self-Citation Percentage |
5.96%
|
|
High, Katherine A.
Spark Therapeutics, Inc.,
United States
2022 Rank: 18084
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Biotechnology
Rank in SubField 1: 504 out of 138599 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 18084 | 18171 |
| Total Cites | 2030 | 2241 |
| H-index | 20 | 22 |
| Hm-index | 7 | 7 |
| Number of Single Authored Papers | 25 | 25 |
| Total Cites to Single Authored Papers | 15 | 15 |
| Number of Single+First Authored Papers | 33 | 33 |
| Total Cites to Single+First Authored Papers | 113 | 113 |
| Number of Single+First+Last Authored Papers | 134 | 134 |
| Total Cites to Single+First+Last Authored Papers | 782 | 846 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 1037 | 1075 |
| Ratio of Total Citations to Distinct Citing Papers | 1.96 | 2.08 |
| Self-Citation Percentage |
9.42%
|
|
High, Katherine A.
Spark Therapeutics, Inc.,
United States
2021 Rank: 21746
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Biotechnology
Rank in SubField 1: 553 out of 127911 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 21746 | 21421 |
| Total Cites | 3108 | 3467 |
| H-index | 25 | 28 |
| Hm-index | 7 | 8 |
| Number of Single Authored Papers | 25 | 25 |
| Total Cites to Single Authored Papers | 18 | 18 |
| Number of Single+First Authored Papers | 33 | 33 |
| Total Cites to Single+First Authored Papers | 146 | 147 |
| Number of Single+First+Last Authored Papers | 133 | 133 |
| Total Cites to Single+First+Last Authored Papers | 1166 | 1286 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 1573 | 1621 |
| Ratio of Total Citations to Distinct Citing Papers | 1.98 | 2.14 |
| Self-Citation Percentage |
10.35%
|
|
High, Katherine A.
Spark Therapeutics, Inc.,
United States
2020 Rank: 25711
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Biotechnology
Rank in SubField 1: 590 out of 108509 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 25711 | 26128 |
| Total Cites | 2253 | 2587 |
| H-index | 23 | 24 |
| Hm-index | 7 | 7 |
| Number of Single Authored Papers | 29 | 29 |
| Total Cites to Single Authored Papers | 13 | 13 |
| Number of Single+First Authored Papers | 41 | 41 |
| Total Cites to Single+First Authored Papers | 56 | 56 |
| Number of Single+First+Last Authored Papers | 136 | 136 |
| Total Cites to Single+First+Last Authored Papers | 833 | 943 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 1060 | 1098 |
| Ratio of Total Citations to Distinct Citing Papers | 2.13 | 2.36 |
| Self-Citation Percentage |
12.91%
|
|
Related Profiles
Featured Profiles
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.